Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort - Quiz - MDSpire

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

  • By

  • Jakob Stögbauer

  • Moritz Bewarder

  • Linda Groß

  • Lorenz Thurner

  • Klaus Fassbender

  • Rebecca Urschel

  • Einar A. Høgestøl

  • Gro O. Nygaard

  • Hanne F. Harbo

  • Olaf Stüve

  • Marc Pawlitzki

  • Sven G. Meuth

  • Martina Sester

  • Sergiu Groppa

  • Mathias Fousse

  • May 12, 2026

  • 0 min

Share

Original Source(s)

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

  • by Jakob Stögbauer, Moritz Bewarder, Linda Groß, Lorenz Thurner, Klaus Fassbender, Rebecca Urschel, Einar A. Høgestøl, Gro O. Nygaard, Hanne F. Harbo, Olaf Stüve, Marc Pawlitzki, Sven G. Meuth, Martina Sester, Sergiu Groppa, Mathias Fousse

  • May 12, 2026

Related Content

Enrichment of Immature CD10low Neutrophils in Individuals Diagnosed with Multiple Sclerosis

Marcus Neuroscience Institute to Host 2026 Brain & Spine Symposium

Marcus Neuroscience Institute, part of Baptist Health South Florida, will host its two-day 2026 Brain & Spine Symposium on May 14 and 15.

  • by

  • April 6, 2026

  • 3 min
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis